news
Lilly bolsters leadership team with neuroscience and immunology in mind
Dr Carole Ho joins from Denali Therapeutics and there are…
Dr Carole Ho joins from Denali Therapeutics and there are promotions for Adrienne Brown and Daniel Skovronsky.
List view / Grid view
David Ricks
news
Lilly boosts oral GLP-1 manufacturing capability with new Netherlands facility
The €2.6 billion manufacturing investment complements the recent US manufacturing…
The €2.6 billion manufacturing investment complements the recent US manufacturing expansion for its next potential blockbuster obesity treatment orforglipron.
news
Lilly to site next US manufacturing facility in Texas
The new $6.5 billion Houston site will manufacture active pharmaceutical…
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
news
Lilly picks Virginia for the first of its four new US manufacturing facilities
The new $5 billion manufacturing site is set to become…
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
news
Eli Lilly neuroscience executive Anne White to retire
Her leadership experience spans three decades with Lilly, across multiple…
Her leadership experience spans three decades with Lilly, across multiple therapeutic areas including oncology, neuroscience and infectious disease.
news
Eli Lilly releases topline data for new oral GLP-1
Subject to regulatory approval, the small molecule drug could provide…
Subject to regulatory approval, the small molecule drug could provide a new treatment option for diabetes and obesity, Eli Lilly’s new data suggests.
article
AI in pharmaceutical development: hype or panacea?
Dave Elder reflects on the array of applications for AI…
Dave Elder reflects on the array of applications for AI to facilitate successful drug development, though proof remains elusive.
article
Harnessing the GLP-1R medicine wave
As a promising treatment for type 2 diabetes and obesity,…
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
news
Eli Lilly selects new EVP of Global Quality
The new Executive Vice President (EVP) has over “25 years…
The new Executive Vice President (EVP) has over “25 years of experience and a proven track record of leading strategic quality initiatives”, Eli Lilly and Company shared.
news
Major manufacturing investment to support API production for tirzepatide
Eli Lilly and Company has committed the largest US investment…
Eli Lilly and Company has committed the largest US investment in synthetic medicine active pharmaceutical ingredient (API) manufacturing.
news
Eli Lilly EVP of Global Quality to retire
Following her leading contribution in key manufacturing and quality projects…
Following her leading contribution in key manufacturing and quality projects in Ireland and the US, Eli Lilly and Company’s Executive Vice President (EVP) of Global Quality is set to retire after nearly 35 years of service.
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
news
Lilly to build two new US manufacturing sites
Eli Lilly and Company announces plans to establish two new…
Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.
news
Lilly announces leadership changes and creation of new business units
Eli Lilly and Company have announced executive leadership changes and…
Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.
news
EMA concludes review of Lilly’s COVID-19 antibody therapies
The human medicines committee decided that there was significant evidence…
The human medicines committee decided that there was significant evidence to endorse the use of a combination of bamlanivimab and etesevimab in outpatients at high risk of severe COVID-19.
news
US to receive 300,000 vials of experimental COVID-19 antibody therapy
Eli Lilly will provide the US government with vials of…
Eli Lilly will provide the US government with vials of its COVID-19 antibody therapy bamlanivimab (LY-CoV555) if the treatment is granted Emergency Use Authorisation.
